Haemonetics Corporation reported $1.35B of revenue over the trailing twelve months, +0.44% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.35B (to Q1 2027). Net income: $96M, trailing twelve months to Q1 2027. Free cash flow: $291M, trailing twelve months to Q1 2027. Operating margin: 12%, trailing twelve months to Q1 2027.

HAEHaemonetics Corporation

Healthcare

$118.73+135% 1Y

$118.73

$47.6752 weeks$119.59

HAE as reported

Haemonetics Corporation reported $1.35B of revenue over the trailing twelve months, +0.44% on the year before. 11 reported series are charted on this page, each one as filed.

$1.35B

Revenue, trailing twelve months · to Q1 2027 · +0.44% against the twelve months before

Net income: $96M
Net income · −41% year on year · trailing twelve months to Q1 2027
Free cash flow: $291M
Free cash flow · +54% year on year · trailing twelve months to Q1 2027
Operating margin: 12%
Operating margin · trailing twelve months to Q1 2027

Details›

Every series Ryufin has for HAE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.35B	+0.44%	Q1 2027
Net income	$96M	−41%	Q1 2027
EPS	$2.07	−37%	Q1 2027
Gross margin	59%	n/a	Q1 2027
Operating margin	12%	n/a	Q1 2027
Net margin	7.2%	n/a	Q1 2027
ROE	16%	n/a	Q1 2027
ROA	5.5%	n/a	Q1 2027
ROIC	9.0%	n/a	Q1 2027
Free cash flow	$291M	+54%	Q1 2027
P/E	57.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.